Evaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metanálisis

Ruiz-Aragón, Jesús; Márquez-Peláez, S.

doi:10.1016/j.acuro.2010.02.019

Cited by 24 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Madeira et al (2015) reported a global diagnostic OR of 38.92 (95% CI (17.82–84.99); Q = 41.2, p = 0.0001; I 2 = 73.3%). These results are similar to those obtained in the current meta-analysis in as much as their OR value is high and statistically significant, although the confidence interval was substantially wide [40,41]…”

Section: Discussionsupporting

confidence: 88%

“…This is ratified by the results obtained in this paper and others, such as the meta-analysis proposed by Ruiz and Márquez (2010), who evaluated the detection of the PCA3 gene product through antigen detection in urine samples, as a biomarker for prostate cancer. This group of researchers reported heterogeneity in global sensitivity and specificity of 63% and 74%, respectively, and reported an area under the curve of 0.73 [41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: A systematic review and meta-analysis

2019

View full text Add to dashboard Cite

Background This meta-analysis presents evidence regarding the diagnostic accuracy of mammaglobin detected using the RT-PCR technique, related to the presence of sentinel node metastasis in breast cancer patients. Methods The following databases were consulted: Cochrane, Lilacs, Scielo, Hinary, PubMed, Elsevier, Embase, ProQuest, the Universidad del Rosario´s Centro de Recursos Para el Aprendizaje y la Investigación (CRAI-UR) [Resource Center for Learning and Research], and the Google Scholar search engine. The quality of the studies was assessed using the QUADAS-2 and CASpe tools. The selected studies presented the necessary data to calculate diagnostic validity index of mammaglobin detection using RT-PCR, compared with the reference standard test. Global values for the sensitivity, specificity, positive predictive value, negative predictive value, probability ratios, diagnostic ORs, and summary ROC curves of this meta-analysis were obtained using the Meta-DiSc 1.4 program. Results Initially, 731 articles were obtained; but only 25 were included in the meta-analysis. Sensitivity was 84% (95% CI: 83% - 86%), and specificity was 92% (95% CI: 91% - 93%). Positive and negative predictive values were 9.26 (95% CI: 6.47–13.26) and 0.17 (95% CI: 0.13–0.23), respectively. The diagnostic OR was 66.34 (95% CI: 42.52–103.52). The predictive area under the sROC curve was 94.78 (Q = 0.8876). Conclusions The evaluated diagnostic index showed that the expression of the mammaglobin biomarker has diagnostic prediction for detecting lymph node metastasis in breast cancer patients, when analyzed using RT-PCR, although more than 50% heterogeneity was found.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: A systematic review and meta-analysis

2019

View full text Add to dashboard Cite

show abstract

“…The diagnostic value of the PCA3 score in patients demonstrated a sensitivity of 46-82%, specificity of 56-89%, PPV of 59-97% and negative predictive value (NPV) of 87-98% 63 - 66 . Such variability can be explained by the fact that different inclusion criteria, cut-off values and protocols were used in these studies.…”

Section: Detection Of Prostate Cancer Biomarkers In Clinical Samplesmentioning

confidence: 99%

Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer

Kanyong¹,

Rawlinson²,

Davis³

2016

J. Cancer

View full text Add to dashboard Cite

Prostate cancer (PCa) is a significant cause of morbidity and mortality and the most common cancer in men in Europe, North America, and some parts of Africa. The established methods for detecting PCa are normally based on tests using Prostate Specific Antigen (PSA) in blood, Prostate cancer antigen 3 (PCA3) in urine and tissue Alpha-methylacyl-CoA racemase (AMACR) as tumour markers in patient samples. Prior to the introduction of PSA in clinics, prostatic acid phosphatase (PAP) was the most widely used biomarker. An early diagnosis of PCa through the detection of these biomarkers requires the availability of simple, reliable, cost-effective and robust techniques. Immunoassays and nucleic acid detection techniques have experienced unprecedented growth in recent years and seem to be the most promising analytical tools. This growth has been driven in part by the surge in demand for near-patient-testing systems in clinical diagnosis. This article reviews immunochemical assays, and nucleic-acid detection techniques that have been used to clinically diagnose PCa.

show abstract

“…Given this situation, new diagnostic methods have emerged, such as prostate cancerspecific antigen 3 (PCA3), which is a marker that detects overexpression of the PCA3 gene by molecular techniques. As the name implies, PCA3 is specific for prostate cancer, and it is expressed only in this disease and is not affected by benign conditions, as occurs with PSA, thereby decreasing the risk of false positives [3].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis

Rodríguez

García‐Perdomo

2019

CUAJ

View full text Add to dashboard Cite

Introduction: We aimed to determine the diagnostic accuracy of the prostate cancer antigen 3 (PCA3) test before performing the first biopsy compared with prostate biopsy for the diagnosis of prostate cancer. Methods: A systematic search was performed in MEDLINE, EMBASE, CENTRAL, LILACS, reference lists, specialized journals in urology and cancer, and unpublished literature. The population was adults with suspected prostate cancer, and the intervention was the measurement of PCA3 in urine samples for the diagnosis of prostate cancer. The quality of studies was evaluated with the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The operative characteristics were determined, and a meta-analysis was performed. Results: Nine studies of diagnostic tests were included based on a cutoff value of 35. The following overall values were obtained: the sensitivity was 0.69 (95% confidence interval [CI] 0.61–0.75); specificity was 0.65 (95% CI 0.553–0.733); the diagnostic odds ratio (DOR) was 4.244 (95% CI 3.487–5.166); and the area under the curve was 0.734 (95% CI 0.674–0.805) with a heterogeneity of 0%. Conclusions: Urinary PCA3 has an acceptable diagnostic accuracy, aids in the study of patients with suspected prostate cancer, and can be used as a guide for directing the performance of the first prostate biopsy and decreasing unnecessary biopsies.

show abstract

Evaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metanálisis

Cited by 24 publications

References 28 publications

Detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: A systematic review and meta-analysis

Detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: A systematic review and meta-analysis

Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer

Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis

Contact Info

Product

Resources

About